Perimeter Schedules Second Quarter 2026 Financial Results Conference Call for August 20th
MWN-AI** Summary
Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) has announced the scheduling of its Second Quarter 2026 financial results conference call for August 20, 2026. The company will disclose its financial and operational results following the market close, with a conference call and webcast led by management at 5:00 PM Eastern Time.
Investors can participate by dialing in via toll-free numbers (1-800-717-1738 for Canada and the U.S., or 1-646-307-1865 internationally). The call will also be available for live streaming and archived on Perimeter’s website for later access.
In addition to the quarterly results, Perimeter confirmed details regarding the closing of its May 2026 offering, where the company issued an additional 1,955,500 units at a price of $0.35 each, resulting in gross proceeds of C$684,425. This issuance brought the total size of the offering to 21,489,000 units, totaling C$7,521,150, and included a cash commission paid and additional broker warrants issued.
Perimeter Medical Imaging specializes in transforming cancer surgery through advanced imaging solutions. Its latest FDA-approved device, the Claire™ system, provides real-time imaging with AI-enabled detection capabilities, designed for use during surgical procedures in women diagnosed with breast cancer. Notably, the Claire system complements traditional histopathology methods rather than replacing them.
As the conference call approaches, forward-looking statements regarding Perimeter's future operations, product efficacy, and market conditions underline the inherent uncertainties in the medical technology field. Investors are encouraged to stay informed and participate in the upcoming call for comprehensive insights into Perimeter’s performance and strategic outlook.
MWN-AI** Analysis
As investors prepare for Perimeter Medical Imaging AI, Inc.'s second quarter 2026 financial results conference call scheduled for August 20, 2026, several market dynamics and strategic factors warrant careful consideration.
Perimeter, known for its innovative Claire™ OCT System, continues to make strides in the medical imaging sector, particularly focusing on cancer surgery enhancement. The company's recent success in securing additional funding of approximately C$684,425 from its May offering indicates strong investor confidence and provides necessary capital for ongoing clinical and regulatory activities. The total offering raised C$7.52 million, supporting the company’s operational and growth initiatives.
Key indicators to watch during the earnings call include revenue growth driven by device adoption rates, updates on clinical trials, and regulatory progress—especially concerning the FDA approval trajectory for future devices. Given the increasing emphasis on minimally invasive procedures and personalized medicine, strong results could reflect positive market reception for the Claire™ OCT System, positioning Perimeter well for future scalability.
Furthermore, as a publicly traded entity on the TSX Venture Exchange and OTCQX, Perimeter's announcements will likely influence stock volatility. Traders should monitor any guidance on future earnings or potential partnerships that could enhance product reach and market penetration.
While Perimeter appears to be capitalizing on an unmet need in breast cancer care, investors should remain cautious of sector-wide risks, including competition and regulatory hurdles. It’s prudent to assess both short-term results and long-term strategic direction, balancing optimism from potential growth with the inherent risks associated with biotech investments. Investors should also consider any upcoming catalysts before positioning in this innovative medical technology space.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Canada NewsWire
TORONTO and DALLAS, Aug. 13, 2026 /CNW/ -- Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, announced it will report its second quarter 2026 financial and operating results after market close on Thursday, August 20, 2026. Following the announcement, Perimeter management will host a webcast and conference call to discuss the results and provide a corporate update.
Second Quarter Results Conference Call Details:
Date: | Thursday, August 20, 2026 |
Time: | 5:00 pm Eastern Time |
Dial-In Numbers: | 1-800-717-1738 (Canada and the United States) or 1-646-307-1865 (International) |
The call will also be broadcast live and archived on the Company's website here.
Clarification Regarding Closing of May 2026 Offering
In addition, further to its previous press release, dated May 5, 2026, the Company confirmed that it issued an additional 1,955,500 units at a price of $0.35 per unit, for additional gross proceeds of C$684,425, on May 8, 2026, in a final tranche of its offering conducted under the listed issuer financing exemption (the "Life Offering"), to bring the total offering up to the maximum offering size of 21,489,000 units (C$7,521,150). The Company also confirmed that it paid an additional cash commission of approximately C$47,910 and issued an additional 136,885 Broker Warrants in connection with the closing of the final tranche of the Life Offering.
About Perimeter Medical Imaging AI, Inc.
Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V: PINK) (OTCQX: PYNKF) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Claire™, recently approved by the U.S. Food and Drug Administration (FDA), is our next-generation AI-enabled device. The Company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month.
Indications for Use: The Claire OCT System is an adjunctive three-dimensional imaging tool which provides volumetric cross-sectional, real-time depth visualization, coupled with an artificial intelligence computer-aided detection algorithm which identifies and marks focal areas suspicious for breast cancer. It is used concurrently with physician interpretation of the images. The Claire OCT System is intended for use in conjunction with other standard methods for evaluation of the margins of excised lumpectomy tissue during surgical procedures in patients with a biopsy-confirmed diagnosis of breast cancer.
The Claire OCT System should not be used to replace standard tissue histopathology assessment and should not be used for diagnosis. The device is not intended for use in any of the following individuals: under the age of 18, male, have metastatic cancer (Stage IV), have lobular carcinoma as their primary diagnosis, have had previous ipsilateral breast surgery for benign or malignant disease within two years (including implants and breast augmentation), patients with multi-centric disease (histologically diagnosed cancer in two different quadrants of the breast), unless resected in a single specimen, patients with bilateral disease (diagnosed cancer in both breasts), patients who are currently lactating, patients who are currently pregnant, or concurrent use in surgeries with cryo-assisted localization. Refer to prescriber labeling for full safety information.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, information regarding the potential benefits of Perimeter's S-Series and B-Series OCT systems, and Perimeter's ongoing clinical, regulatory, and commercialization activities, are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Management Discussion and Analysis and Annual Information Form for the year ended December 31, 2024, which are available on Perimeter's SEDAR+ profile at https://www.sedarplus.ca, and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws.
CONTACTS:
Stephen Kilmer
Investor Relations
Direct: 647-872-4849
Email: skilmer@perimetermed.com
Adrian Mendes
Chief Executive Officer
Toll-free: 888-988-7465 (PINK)
Email: investors@perimetermed.com
SOURCE Perimeter Medical Imaging AI Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/August2026/13/c5048.html
FAQ**
What key financial metrics should we expect from Perimeter Medical Imaging AI Inc PYNKF during the second quarter of 2026, and how do they compare to previous quarters?
Can you elaborate on any recent developments or advancements in the Claire OCT System that may influence Perimeter Medical Imaging AI Inc PYNKF's growth and market positioning?
What specific challenges or risks does management anticipate for Perimeter Medical Imaging AI Inc PYNKF in the upcoming quarters, particularly in relation to regulatory approvals or market competition?
How does Perimeter Medical Imaging AI Inc PYNKF plan to utilize the proceeds from the recent offering to drive research, development, and commercialization efforts moving forward?
**MWN-AI FAQ is based on asking OpenAI questions about Perimeter Medical Imaging AI Inc (OTC: PYNKF).
NASDAQ: PYNKF
PYNKF Trading
-2.05% G/L:
$0.2057 Last:
117,999 Volume:
$0.21325 Open:
PYNKF Latest News
